Furthermore, mechanistic insights revealed that aleplasinin-mediated inhibition of PAI1 not only inhibited cell migration but also sensitised HER2-positive breast cancer cells to trastuzumab, suggesting a dual benefit of overcoming resistance and enhancing drug efficacy. Here, ERBB2 is linked to breast carcinoma.